Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe visible change is a minor revision label updated from v3.4.1 to v3.4.2; no alterations to the study content, eligibility criteria, or essential page functionality are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page shows a minor version update from v3.4.0 to v3.4.1. There are no observed changes to core study content, eligibility criteria, or outcomes; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedGlossary is now shown on the page, and QC-related metadata has been updated to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing previous wording/capitalization. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated to v3.3.4, replacing the previous v3.3.3.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter shows Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.